Bioactive lipids in inflammatory bowel diseases - From pathophysiological alterations to therapeutic opportunities
ReviewHumansOther animals
- Design
- Review
- Subjects
- Not stated in the abstract
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- How lipid mediators — fatty acids, specialised pro-resolving mediators, lysophospholipids, endocannabinoids including N-acylethanolamines, and oxysterols — are altered in Crohn's disease and ulcerative colitis, and where they could be targeted therapeutically.
What the authors reported
The abstract does not single out palmitoylethanolamide findings or give numbers. The authors describe how lipid signalling is involved in inflammatory bowel disease and how altering lipid pathways could affect the disease.
Limits of this study
A narrative review of selected examples, not a systematic review or trial. Palmitoylethanolamide is one of many lipids discussed. Funding and conflicts not stated in the abstract.
Source
PubMed 33157277 · doi:10.1016/j.bbalip.2020.158854
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.